Friday 6 November 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue: +1.44%
EPS: −21.5%
Free cash flow: −25.3%
Total debt: +3.04%

Quarter to September 2026, against a year earlier

42.73 1.91 −4.28%

Follow BSX

Alert me

Market cap: $64.7B
P/E: 18.0×
Fwd P/E: 17.0×
Dividend yield: —
F-score: 7/9
Altman Z: 5.41
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Boston Scientific Corporation 10-K filed Feb 18, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 18, 2025 · accepted 4:13 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business: no comparison — no earlier filing on file